U.S. markets close in 36 minutes

Bicycle Therapeutics plc (BCYC)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
21.99+0.14 (+0.64%)
A partir del 03:24PM EDT. Mercado abierto.

Bicycle Therapeutics plc

Portway Building
Blocks A & B Granta Park Great Abington
Cambridge CB21 6GS
United Kingdom
44 1223 261 503
https://www.bicycletherapeutics.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo284

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Kevin Lee M.B.A., Ph.D.CEO & Executive Director1.35MN/D1968
Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSECo-Founder & Non-Executive Director57.75kN/D1951
Ms. Alethia Rene YoungChief Financial Officer581.69kN/D1979
Dr. Santiago Arroyo M.D., Ph.D.Chief Development Officer916.98kN/D1960
Dr. Christian HeinisScientific FounderN/DN/DN/D
Mr. Alistair MilnesChief Operating Officer796.09kN/D1974
Mr. Travis ThompsonSenior VP, Chief Accounting Officer & Principal Accounting OfficerN/DN/DN/D
Dr. Michael Skynner B.sc. Ph.d., Ph.D.Chief Technology Officer881.01kN/D1969
Dr. Nicholas Keen Ph.D.Chief Scientific OfficerN/DN/D1968
Mr. Zafar QadirGeneral CounselN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Gestión corporativa

La calificación ISS Governance QuickScore de Bicycle Therapeutics plc a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.